Life Biosciences reported interim Phase 1 data for ER-100, an intravitreal gene therapy delivering doxycycline-inducible OSK transcription factors to retinal ganglion cells in open-angle glaucoma. A single low-dose administration was tolerated through Day 56 in all three participants with no dose-limiting toxicities, and two of three showed improvements in Humphrey visual field testing, with at least 28% of tested points improving by more than 4 dB. The independent safety board recommended escalation to the second dose level, marking the first human tolerability data for partial epigenetic reprogramming.
Key Points
- Partial OSK reprogramming tolerated in first three human participants
- Two of three glaucoma patients showed visual field improvement
- Safety board cleared escalation to higher dose level
Longevity Analysis
Retinal ganglion cells do not naturally regenerate, which makes the optic nerve a demanding proving ground for any claim that cellular age can be partially reversed rather than merely slowed. Moving a reprogramming construct into living human tissue — with inducible, time-limited expression and a steroid taper to blunt the immune reaction to the viral vector — shifts the central question from whether rejuvenation is biologically possible to whether it can be controlled precisely enough to be safe. Three participants and 56 days establish nothing definitive, but the measurement endpoint matters: visual field testing reads out functional neural capacity, not a surrogate marker, and it is the kind of signal that distinguishes genuine tissue restoration from biochemical noise.
Original published by LifeSpan.io, by Press release.